Skip to search formSkip to main contentSkip to account menu

rifaximin

Known as: 4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin, Rifaximinun, rifaximin [Chemical/Ingredient] 
An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta… 
National Institutes of Health

Related topics

Related topics

10 relations
Anti-Bacterial AgentsBacterial InfectionsRifamycinsRifaximin:Susc:Pt:Isolate:OrdQn

Broader (3)

Anti-Infective AgentsGastrointestinal AgentsNucleic Acid Synthesis Inhibitors

Narrower (1)

L 105 (rifaximin)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases
Gut microbiota dysbiosis contributes to the pathogenesis of inflammatory bowel diseases (IBD). Although the microbiota's role in… 
2014
2014
Microbiota, infecciones gastrointestinales, inflamación de bajo grado y antibioticoterapia en el síndrome de intestino irritable. Una revisión basada en evidencias
Review
2013
Review
2013
Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
Review
2012
Review
2012
Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.
The gut flora plays an important role in the pathogenesis of the complications of cirrhosis. Hepatic encephalopathy (HE… 
Review
2011
Review
2011
Biologic properties and clinical uses of rifaximin
Introduction: Rifaximin is increasingly being used to treat acute and chronic gastrointestinal infections and disorders. The drug… 
Review
2010
Review
2010
Current and emerging strategies for treating hepatic encephalopathy.
Review
2007
Review
2007
Advances in defining etiology and new therapeutic approaches in acute diarrhea.
Review
2005
Review
2005
Rifaximin: a nonabsorbed oral antibiotic.
Rifaximin is a rifamycin analogue with a broad spectrum of activity similar to that of rifampin; however, because it is poorly… 
1999
1999
[Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results].
In order to evaluate the efficacy and tolerability of mesalazine (5-ASA) in the prophylaxis of symptomatic relapses, of major… 
Highly Cited
1999
Highly Cited
1999
Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections.
In HIV-1 infected patients severe enteritis and chronic diarrhea are often documented as a consequence of multiple opportunistic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)